We hope you well and healthy. Here are the Medical Supplies we provide below: 1. COVID-19 TEST KIT(AG/lgG+lgM) 2. Hand Sanitizer 3. KF94 masks 4. 3ply Dental masks 5. Nitrile Gloves 6. Gowns 7. Sampling swab kits If you have any questions or if you interested in our product, please do not hesitate to contact us. Waiting for hearing from you. we wish you stay well and healthy. Thank you. Sincerely,
We provide our Best quality product's information.And also, CE approved, FDA emergency use approval and officially permanent approval in progress . KFDA approved. 100% MADE IN KOREA Product Name COVID-19 IgM/IgG test Rapid immunoassay for COVID-19 infection marynkorea.ltd@gmail.com
We provide our Best quality product's information.And also, CE approved, KFDA approved, FDA emergency use approval and officially permanent approval in progress . MDSAP approved. ISO 13485 MADE IN KOREA Home testing and Hospital testing available. This kit can be stored in room temperature. Product Name: GenBody COVID-19 IgM/IgG price list 8.5 USD each. MOQ 10,000 KIT (10,000 people test) marynkorea.ltd@gmail.com whatsapp: 821080330163
We provide our Best quality product's information.And also, CE approved, KFDA approved, FDA emergency use approval and officially permanent approval in progress . MDSAP approved. ISO 13485 MADE IN KOREA Home testing and Hospital testing available. This kit can be stored in room temperature. Product Name: GenBody COVID-19 IgM/IgG price list 11.45 USD each. MOQ 10,000 KIT (10,000 people test)
We provide our Best quality product's information.And also, CE approved, FDA emergency use approval and officially permanent approval in progress . KFDA approved. 100% MADE IN KOREA Product Name COVID-19 IgM/IgG test Rapid immunoassay for COVID-19 infection
1. Detect whether patient infected or not in 10 Minute. 2. But the patient need to wait over 5 days from infected at least. 3. USD 5.5 means for 1 person. (FOB) 4.Do not require Expert and expensive instrument. 5. PCR kit required to be kept in -20 C degree but this kit can be stored in room temperature. 6. CE certificate secured, ISO 13485 secured.
This is Berenice Hong, working at EQC27 in Korea. We would like to sell COVID19 Test Kits ( FDA & EUA approved, made by Korea) to extend our business line with you. If you are interested in as a buyer or an introducing broker, please let us know. If you want to have any further inquiry, please reply back. We can do further discussion such as video meetings, sharing brochures of the product that you may need. *COVID19 Detection Kits(* price negotiable) 1. RT-PCR tests (1) Made in Korea (2) Over 1M tests : (3) Over 3M tests : (4) Over 5M tests : (5) EUA(Emergency Use Authorization), CE-IVD 2. Anti-body tests (1) Made in Korea (2) Test result is known within 10 mins. (3) FDA listed : (4) FDA non-listed : 3. Order Process (1) (Buyer) Submit a LOI including potential buyers' name, location, the person in charge, product-type, quantity, etc. (2) (Seller) Provide product's info. (3) (Buyer) Make an payment(T/T). (4) (Seller) Ship the products(EXW).
Offering COVID-19 test kit here as follows; 1) 1 kit for 100 test cost $3,300 FOB 2) Sample order MOQ = 1 kit plus 800 USD for FEDEX air-shipping. (shipping cost will be vary depend on location) 3) FDA/ CE approved 4) Korean product Detail information will be sent by email if you provide to me. Please consider it and do not hesitate to contact me at any time.
In vitro diagnostic test.
HPV NGS Kit is an in vitro diagnostic test that simultaneously detects the genotype of human papillomavirus (HPV) using Next-Generation Sequencing technology (NGS). Automated workflows allow for fewer human errors and less hands-on time from library construction to analysis of results. HPV types are quickly identified by simultaneously analyzing up to 480 samples. NGS time is reduced to approximately 24 hours.
Ezplex HLA-B NGS typing Kit is an in vitro diagnostic test that detects and distinguishes allelic genes of HLA-B in human leukocyte antigens at high resolution using next-generation sequencing. Ezplex's unique amplicon approach simplifies the traditional complex NGS Library construction process and provides dedicated software optimized for HLA typing for easy analysis. The Ezplex HLA-B NGS typing Kit accurately reads the HLA-type Acuracy (95 percent Confidence Interval) in DRB1 Locus within a total of 35 hours from DNA extraction to NGS results analysis to help with pre-transplant testing.
Corona test kit from South Korea. Approval by FDA, CE, FSC. Kits have been exported to Europe, North America, South America, etc. Price : EXW KOREA and US$ 15 MOQ : 1,000Kits(can be used for 100,000cases) Payment Terms : T/T 100% In advance. Delivery : Contacted DHL. Production : within a week. User have to equip RT-PCR. We need to check which one you have.
INTENDED USE A rapid animal diagnostic test kit for simple antigen detection that can check the presence of coronavirus antigens in dog feces and diagnose the sample with a simple operation within 10 minutes. Symptom of a disease The virus that enters the dogs mouth reaches the small intestines through the stomach, multiplies in the mucous membrane, secretes toxic substances, and destroys the intestinal mucous membrane. The main symptoms of coronavirus are enteritis or diarrhea. However, it is not fatal and shows symptoms such as vomiting and dehydration.
INTENDED USE A rapid animal diagnostic test kit for simple antigen detection that can check the presence of parvovirus antigens in dog feces and diagnose the sample with a simple operation within 10 minutes. Symptom of a disease It is infected by contact or oral cavity through the feces of an infected dog. Symptoms are diarrhea and are highly contagious diseases. The parvovirus first develops within 48 to 72 hours. In dogs infected for more than eight weeks, it usually causes vomiting, stinky gray diarrhea or bloody excrement, rapid weakness, and loss of appetit
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
